636 ka bata naluwas sa pag-abusoSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium ® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries. Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. “We are very excited to share validation data of our MRD assay. SABCS gives us the opportunity to showcase our clinical expertise in the prevention and treatment of early and advanced breast cancer,” said George Daneker, MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. “Myriad is one of the only labs that can offer germline and tumor genomic testing, combined with customizable workflow solutions and point-of-care patient education sessions. Our test results are supported by treatment-focused reporting, concordance checks between germline and tumor genomic results, and a summary sheet designed to help oncologists and breast surgeons interpret actionable insights more effectively.” Myriad Genetics Data Presentations Spotlight Presentation: Session 16, PS16-01: Polygenic Risk Date: Thursday, Dec. 12, 2024, 5:30-7:00 pm (CST), Hemisfair Ballroom 3 Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics The presentation will share longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors. Rapid-Fire Presentation: RF1-06 Date: Wednesday, Dec. 11, 2024, 12:00-12:50 pm (CST), Hall 1 Presenter: Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics Dr. Johansen Taber will share data detailing the association of polygenic-based breast cancer risk prediction with patient management. Poster Presentation: P2-04-23 Date: Wednesday, Dec. 11, 2024, 5:30-7:00 pm (CST), Halls 2-3 Presenter: Ashley Acevedo, PhD, Staff Computational Scientist, Myriad Genetics This poster shares the analytical validation of a high-definition tumor-informed Molecular Residual Disease (MRD) assay to demonstrate robust detection at low-tumor fractions, which are common in breast cancer. Poster Presentation: P3-02-10 Date: Thursday, Dec. 12, 2024, 12:30-2:00 pm (CST), Halls 2-3 Presenter: Holly Pederson, MD, Cleveland Clinic Dr. Pederson will share her evaluation of a polygenic risk score as a predictor of breast cancer, triple-negative breast cancer, and early-onset disease in Hispanic women. In addition to data presentations, Myriad will welcome attendees to its booth (#1327) during exhibition hours. Among the Myriad products highlighted in the company’s SABCS exhibit are: MyRisk ® Hereditary Cancer Test evaluates 48 genes to help healthcare providers identify their patients’ risk of developing 11 different types of hereditary cancer. MyRisk’s clear, actionable results are the foundation for personalized care plans to help patients make confident, informed decisions about medical management. MyRisk with RiskScore ® provides unaffected patients with a comprehensive, personalized assessment of the five-year risk and remaining lifetime risk of developing breast cancer. Precise Tumor ® Molecular Profile Test is a pan-cancer solid tumor comprehensive genomic profiling test that helps clinicians with straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic result. MyChoice ® CDx is one of the most comprehensive homologous recombination deficiency (HRD) tests available, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). EndoPredict ® Breast Cancer Prognostic Test is for patients with ER+ , HER2- , node negative or node positive breast cancer. The test provides three individualized results used to help determine the most appropriate breast cancer treatment. About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com . Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company will present new data at SABCS and that the company’s new data that will be shared at SABCS will show how the company’s second-generation tumor-informed MRD assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec 9, 2024-- Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209400549/en/ Dr. Martin Madaus (Photo: Business Wire) Dr. Madaus, who has more than 30 years of diagnostics and life sciences industry experience, currently serves as an Operating Executive at the Carlyle Group, a global investment firm, which he joined in February 2019. Prior to joining the Carlyle Group, Dr. Madaus held the role of Chairman and Chief Executive Officer at Ortho Clinical Diagnostics, Inc., a diagnostics company that makes products and diagnostic testing equipment for blood testing. Dr. Madaus previously served as the Chairman, President and Chief Executive Officer of Milipore Corporation, a life sciences company serving the bioscience research and biopharmaceutical manufacturing industry, until its acquisition by Merck KGaA in 2010. “We’re delighted to welcome Martin to Hologic’s Board of Directors,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “With his deep industry, technical, business and international experiences, Martin represents yet another strong addition to our deep and experienced Board.” Dr. Madaus received a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany. About Hologic, Inc. Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com . Forward Looking Statements This press release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions, and statements regarding the Company's Board of Directors. These forward-looking statements are based on assumptions made by the Company as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, the risk that the Company may not be able to attract and retain qualified Board members or executives. These risks are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented here to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. SOURCE: Hologic, Inc. View source version on businesswire.com : https://www.businesswire.com/news/home/20241209400549/en/ CONTACT: Investor Contact: Ryan Simon +1 858.410.8514 ryan.simon@hologic.comMedia Contact: Bridget Perry +1 508.263.8654 bridget.perry@hologic.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES CONSUMER WOMEN HEALTH TECHNOLOGY GENERAL HEALTH BIOTECHNOLOGY SOURCE: Hologic, Inc. Copyright Business Wire 2024. PUB: 12/09/2024 04:05 PM/DISC: 12/09/2024 04:05 PM http://www.businesswire.com/news/home/20241209400549/en
None
The 50 best wines under $50 from our critic, who tasted 4,223Readers' Favorite recognizes "Her Alibi" by Mary L Schmidt in its annual international book award contest 12-09-2024 11:30 PM CET | Leisure, Entertainment, Miscellaneous Press release from: Getnews / PR Agency: Kjprnews Image: https://www.getnews.info/wp-content/uploads/2024/12/1733638126.jpeg Readers' Favorite recognizes "Her Alibi" by Mary L Schmidt in its annual international book award contest, currently available at http://www.amazon.com/gp/product/B0BCQ54H44 . The Readers' Favorite International Book Award Contest featured thousands of contestants from over a dozen countries, ranging from new independent authors to NYT best-sellers and celebrities. Image: https://m.media-amazon.com/images/I/41lNgBL6hnL._SL400_.jpg Readers' Favorite is one of the largest book review and award contest sites on the Internet. They have earned the respect of renowned publishers like Random House, Simon & Schuster, and Harper Collins, and have received the "Best Websites for Authors" and "Honoring Excellence" awards from the Association of Independent Authors. They are also fully accredited by the BBB (A+ rating), which is a rarity among Book Review and Book Award Contest companies. We receive thousands of entries from all over the world. Because of these large submission numbers, we are able to break down our contest into 140+ genres, and each genre is judged separately, ensuring that books only compete against books of their same genre for a fairer and more accurate competition. We receive submissions from independent authors, small publishers, and publishing giants such as Random House, HarperCollins and Simon & Schuster, with contestants that range from the first-time, self-published author to New York Times bestsellers like J.A. Jance, James Rollins, and #1 best-selling author Daniel Silva, as well as celebrity authors like Jim Carrey (Bruce Almighty), Henry Winkler (Happy Days), and Eriq La Salle (E.R., Coming to America). "When the right books are picked as winners we pay attention. We will be spreading the word about Readers' Favorite." - Karen A., Editor for Penguin Random House Readers' Favorite is proud to announce that "Her Alibi" by Mary L Schmidt won the Silver Medal in the Non-Fiction - Relationships category. You can learn more about Mary L Schmidt and "Her Alibi" at https://readersfavorite.com/book-review/her-alibi where you can read reviews and the author's biography, as well as connect with the author directly or through their website and social media pages. Media Contact Company Name: Readers' Favorite LLC Contact Person: Media Relations Email: Send Email [ http://www.universalpressrelease.com/?pr=readers-favorite-recognizes-her-alibi-by-mary-l-schmidt-in-its-annual-international-book-award-contest ] Phone: 800-RF-REVIEW City: Louisville State: KY 40202 Country: United States Website: https://readersfavorite.com This release was published on openPR.The Art and Precision of Investment Casting Manufacturing: A Deep Dive